Comparative Study of Changing of Fibrocystic Breast Change in Breast Cancer Patient from Effect of Tamoxifen

Abstract

Background: The prevalence of fibrocystic changes is about 30 to 60 percent and 0.3 percent of complexcysts is associated with breast cancer. Breast cysts are more commonly presented in premenopausal thanpostmenopausal. Several studies have reported that Tamoxifen could reduce the risk of breast cancer and mastalgiain fibrocystic breast changes. Objective: This study aims to compare the evaluation of the efficacy of Tamoxifenin changing of size and number of breast cysts. Study design was a retrospective study used existing data recordedfrom January 2008 to July 2017. Method: 2,244 women with breast cancer who had undergone mammograms withultrasonogram or ultrasonogram in Surathani Cancer Hospital was collected. Result: Out of 2,244 total patients,77 patients (3.43 percent) had cysts. The cysts were mostly presented in patients within the age group of 41-50years old. Tamoxifen treatment and menstruation status showed no statistically significant difference in the rateof reduction of size or number of cysts analyzed by the chi-square test. The rate of reduction of the size and thenumber of cysts in the patients receiving tamoxifen are 60.7 and 46.4 percent, respectively. The rate of reduction ofthe size and the number of cysts in the patients receiving non-tamoxifen were 50.0 and 35.3 percent, respectively.However, there was no statistical difference (p-value: 0.706 and 0.508, respectively). The rate of reduction of thesize of cysts in the patients during menstruation receiving tamoxifen and non-tamoxifen are 50.0 and 50.0 percent,respectively (p-value: 0.252). The rate of reduction of the size of cysts in the patients without menstruation receivingtamoxifen and non-tamoxifen were 60.0 and 55.6 percent, respectively (p-value: 0.330). The rate of reduction ofthe number of cysts in the patients during menstruation receiving tamoxifen and non-tamoxifen are 55.6 and 25.00percent, respectively (p-value: 0.229). The rate of reduction of the number of cysts in the patients without menstruation receiving Tamoxifen and non-Tamoxifen are 50.0 and 44.5 percent, respectively (p-value: 0.904) Conclusion:Tamoxifen cannot change size and number of breast cysts in both breast cancer patients with menstruation andwithout menstruation